ArticleCroatian medical journal2026
Repressive regulatory function of seryl-tRNA synthetase on VEGFA gene expression is impaired in renal cell carcinoma.
Article in Croatian medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo assess the relationship of the mRNA and protein expression levels of seryl-tRNA synthetase (SerRS) and the expression of gene encoding vascular endothelial growth factor A (VEGFA) in patients with renal cell carcinoma (RCC).
methodsExpression levels of VEGFA and SerRS mRNA were quantified by quantitative real-time polymerase chain reaction in 31 paired RCC tumor and adjacent healthy kidney tissues, while SerRS protein levels were assessed by Western blot analysis in 19 paired samples. The association of SerRS and VEGFA with clinicopathological parameters was evaluated. In addition, bioinformatics analyses were performed using publicly available transcriptomic and proteomic data sets.
resultsVEGFA expression was significantly higher in tumor tissues than in adjacent healthy tissues, while SerRS mRNA levels were similar in both. However, SerRS protein was significantly elevated in tumor tissues. Despite elevated levels of SerRS protein in RCC tumor tissues, SerRS repressive regulatory function on VEGFA was impaired. This dysregulation was associated with increased SerRS phosphorylation, upregulation of several transcriptional activators, and hypomethylation of the VEGFA promoter - factors likely contributing to VEGFA overexpression. Importantly, higher SerRS gene expression was significantly associated with improved overall survival in patients.
conclusionThe findings indicate that various factors diminish SerRS repressor function leading to the VEGFA upregulation in RCC. Survival analysis suggests that SerRS may serve as a valuable prognostic biomarker and represent a potential therapeutic target in RCC.
Indexed as
Identifiers
42104647PMC13181588What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.